THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM)
Strontium ranelate (SR) that has a proven efficacy in reducing the risk of fractures and in increasing bone mineral density is currently recommended as a second choice drug for the treatment of severe osteoporosis (OP) in postmenopausal women and elderly men. Subjects and methods. In 2014–2015, a su...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2018-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2587 |
| _version_ | 1826555937612103680 |
|---|---|
| author | O. A. Nikitinskaya N. V. Toroptsova E. L. Nasonov |
| author_facet | O. A. Nikitinskaya N. V. Toroptsova E. L. Nasonov |
| author_sort | O. A. Nikitinskaya |
| collection | DOAJ |
| description | Strontium ranelate (SR) that has a proven efficacy in reducing the risk of fractures and in increasing bone mineral density is currently recommended as a second choice drug for the treatment of severe osteoporosis (OP) in postmenopausal women and elderly men. Subjects and methods. In 2014–2015, a survey within the framework of the MARC program (The Use of Antiosteoporotic Drugs in Real Clinical Practice) was conducted in 1799 OP patients aged 25 to 92 years, who had been treated for this disease for at least one year. Among the respondents, there were 1696 people aged 50 years and older (mean age, 64±7 years; disease duration, 2.7±2.4 years) (86% women and 14% men) who were the subjects of this survey. Adherence to performed antiosteoporotic therapy was evaluated within the last 12 months before the survey by the following parameters: which drug had been taken; the number of packages used, treatment gaps and compliance with the treatment regimen. Results and discussion. The survey of the patients included in the study showed that 19% of them had received SR at any time over the course of the disease, and 8% had taken the drug within the year preceding the survey. Thus, SR remains a popular drug in real clinical practice for the treatment of severe OP in patients with no history of coronary heart disease, uncontrolled hypertension, cerebrovascular diseases, peripheral artery disease, and a predisposition to thrombosis and thromboembolism. |
| first_indexed | 2024-04-09T22:22:45Z |
| format | Article |
| id | doaj.art-4e324ab94a7645e597777d3aaf2d3dd6 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2025-03-14T08:04:45Z |
| publishDate | 2018-09-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-4e324ab94a7645e597777d3aaf2d3dd62025-03-02T13:23:45ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922018-09-0156442943210.14412/1995-4484-2018-429-4322379THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM)O. A. Nikitinskaya0N. V. Toroptsova1E. L. Nasonov2V.A. Nasonova Research Institute of Rheumatology, MoscowV.A. Nasonova Research Institute of Rheumatology, MoscowV.A. Nasonova Research Institute of Rheumatology, Moscow; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaStrontium ranelate (SR) that has a proven efficacy in reducing the risk of fractures and in increasing bone mineral density is currently recommended as a second choice drug for the treatment of severe osteoporosis (OP) in postmenopausal women and elderly men. Subjects and methods. In 2014–2015, a survey within the framework of the MARC program (The Use of Antiosteoporotic Drugs in Real Clinical Practice) was conducted in 1799 OP patients aged 25 to 92 years, who had been treated for this disease for at least one year. Among the respondents, there were 1696 people aged 50 years and older (mean age, 64±7 years; disease duration, 2.7±2.4 years) (86% women and 14% men) who were the subjects of this survey. Adherence to performed antiosteoporotic therapy was evaluated within the last 12 months before the survey by the following parameters: which drug had been taken; the number of packages used, treatment gaps and compliance with the treatment regimen. Results and discussion. The survey of the patients included in the study showed that 19% of them had received SR at any time over the course of the disease, and 8% had taken the drug within the year preceding the survey. Thus, SR remains a popular drug in real clinical practice for the treatment of severe OP in patients with no history of coronary heart disease, uncontrolled hypertension, cerebrovascular diseases, peripheral artery disease, and a predisposition to thrombosis and thromboembolism.https://rsp.mediar-press.net/rsp/article/view/2587osteoporosisstrontium ranelateclinical practice |
| spellingShingle | O. A. Nikitinskaya N. V. Toroptsova E. L. Nasonov THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM) Научно-практическая ревматология osteoporosis strontium ranelate clinical practice |
| title | THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM) |
| title_full | THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM) |
| title_fullStr | THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM) |
| title_full_unstemmed | THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM) |
| title_short | THE PLACE OF STRONTIUM RANELATE IN THE TREATMENT OF PATIENTS WITH OSTEOPOROSIS (RESULTS OF THE MARC PROGRAM) |
| title_sort | place of strontium ranelate in the treatment of patients with osteoporosis results of the marc program |
| topic | osteoporosis strontium ranelate clinical practice |
| url | https://rsp.mediar-press.net/rsp/article/view/2587 |
| work_keys_str_mv | AT oanikitinskaya theplaceofstrontiumranelateinthetreatmentofpatientswithosteoporosisresultsofthemarcprogram AT nvtoroptsova theplaceofstrontiumranelateinthetreatmentofpatientswithosteoporosisresultsofthemarcprogram AT elnasonov theplaceofstrontiumranelateinthetreatmentofpatientswithosteoporosisresultsofthemarcprogram AT oanikitinskaya placeofstrontiumranelateinthetreatmentofpatientswithosteoporosisresultsofthemarcprogram AT nvtoroptsova placeofstrontiumranelateinthetreatmentofpatientswithosteoporosisresultsofthemarcprogram AT elnasonov placeofstrontiumranelateinthetreatmentofpatientswithosteoporosisresultsofthemarcprogram |